[1]Fasolato S, Angeli P, Dallagnese L, et al.:Renal failure and bac-terial infections in patients with cirrhosis:epidemiology and clinicalfeatures[J].Hepatology, 2007, 45 (1) ∶223-229.
|
[2]Helvig FC, Schutz CB. A liver and kidney syndrome: clinical, pathological, and experimental studies[J]. Surg Gynecol Obstet, 1932, 55 (4) ∶570-582.
|
[3]Gines P, Guevara M, Arroyo V, et al. Hepato-renal syndrome[J]. Lancet, 2003, 362 (9398) ∶1819-1827.
|
[4]Vicente Arroyo, Carlos Terra, Pere Gine`s.Advances in the patho-genesis and treatment of type-1 and type-2 hepatorenalsyndrome[J].Journal of Hepatology, 2007, 46 (5) ∶935-946.
|
[5]Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score[J]. Gastroenterology, 2005, 129 (6) ∶1944-1953.
|
[6]Fasolato S, Angeli P, Dallagnese, L, et al.Renal failure and bac-terial infections in patients with cirrhosis:epidemiology and clinicalfeatures[J].Hepatology, 2007, 45 (1) ∶223-229.
|
[7]Fernandez J, Monteagudo J, Bargallo X, et al.A randomized un-blinded pilot study comparing albumin versus hydroxyethyl starch inspontaneous bacterial peritonitis[J].Hepatology, 2005, 42 (43) ∶627-634.
|
[8]Moore K, Wong F, Gines P, et al.The management of ascites incirrhosis:report on the consensus conference of the international as-cites club[J].Hepatology, 2003, 38 (1) ∶258-266.
|
[9]Gines A, Escorsell A, Gines P, et al.Incidence, predictive factorsand prognosis of the hepato-renal syndrome in cirrhosis with asci-tes[J].Gastroenterology, 1993, 105 (1) ∶229-236.
|
[10]Hennenberg M, Trebicka J, Sauerbruch T, et al. Mechanisms of extrahepatic vasodilation in portal Hypertension[J].Gut, 2008, 57 (9) ∶1300-1314.
|
[11]Sieber CC, Lopeztalavera JC, Groszmann RJ. Role of nitric-oxide in the invitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats[J]. Gastroenterology, 1993, 104 (6) ∶1750-1754.
|
[12]Coll M, GenescàJ, Raurell I, et al.Genetic down-regulation ofgenes related to the adrenergic system might have a role in splanch-nic vasodilation of portal hypertension[J].Journal of Hepatology, 2008, 49 (1) ∶43-51.
|
[13]Geerts AM, De Vriese AS, Vanheule E, et al.Increased angiogen-esis and permeability in the mesenteric microvasculature of rats withcirrhosis and portal hypertension:an in vivo study[J].Liver Int, 2006, 26 (7) ∶889-898.
|
[14]Ruiz-del-Arbol W, Urman J, Fernandez J, et al.Systemic, re-nal, and hepatic hemodynamic derangement in cirrhotic patientswith spontaneous bacterial peritonitis[J].Hepatology, 2003, 38 (5) ∶1210-1218.
|
[15]Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrom cirrhosis[J]. Hepatology, 2005, 42 (2) ∶439-447.
|
[16]Ma ZH, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter[J]. Hepatology, 1996, 24 (2) ∶451-459.
|
[17]Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis[J]. Journal of Hepatology, 2008, 48 (suppl 1) ∶ S93-S103.
|
[18]Arroyo V, Colmenero J.Ascites and hepatorenal syndrome in cir-rhosis:pathophysiological basis of therapy and currentmanagement[J].J Hepatol, 2003, 38 (suppl 1) ∶S69-S89.
|
[19]Wadei HM, Mai ML, Ahsan N, et al.Hepatorenalsyndrome:Patho-physiology and management[J].Clin J AmSoeNePhrol, 2006, 1 (5) ∶1066-1079.
|
[20]Stadlbauer V, Wright GAK, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow auto regulation in cirrhosis[J]. Gastroenterology, 2008, 134 (1) ∶111-119.
|
[21]Papadakis MA, Arieff AI. Unpredictability of clinical-evaluation of renal-function in cirrhosis prospective-study[J]. Am J Med, 1987, 82 (5) ∶945-952.
|
[22]Caregaro L, Menon F, Angeli P, Amodio P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis[J]. Arch Intern Med, 1994, 154 (2) ∶201-205.
|
[23]Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls[J]. Am J Kidney Dis, 2003, 41 (2) ∶269-278.
|
[24]Gtzberger M., Kaiser C, Landauer N, et al.Intrarenal resistanceindex for the assessment of early renal function impairment in pa-tients with liver cirrhosis[J].European Journal of Medical Re-search, 2008, 13 (8) ∶383-387.
|
[1] | Rong SUN, Li JIANG. Research advances in biomarkers for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2023, 39(9): 2225-2230. doi: 10.3969/j.issn.1001-5256.2023.09.029 |
[2] | Jiaqi LIANG, Wen LIU. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 1974-1979. doi: 10.3969/j.issn.1001-5256.2022.09.005 |
[3] | Lihong YANG, Jinhui YANG. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(12): 2770-2773. doi: 10.3969/j.issn.1001-5256.2021.12.006 |
[4] | LI Yan, LU LunGen. Emphasis on the basic and clinical research on hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2401-2405. doi: 10.3969/j.issn.1001-5256.2020.11.001 |
[5] | SONG JingRu, SUN MingYu. Research advances in integrated traditional Chinese and Western medicine therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2561-2564. doi: 10.3969/j.issn.1001-5256.2020.11.037 |
[6] | LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005 |
[7] | CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006 |
[8] | LI Yan, LU LunGen, CAI XiaoBo. Advances in the treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2415-2418. doi: 10.3969/j.issn.1001-5256.2020.11.004 |
[9] | LIAO XianHua, YE JunZhao, ZHONG BiHui. Pathogenesis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2406-2410. doi: 10.3969/j.issn.1001-5256.2020.11.002 |
[10] | Chen LanLan, Han Wen, Liu JingJing, Hu Dan, He WeiWei. Research advances in the biomarkers for the early diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2018, 34(11): 2448-2452. doi: 10.3969/j.issn.1001-5256.2018.11.040 |
[11] | Song TingXue, Qi XingShun, Gao Fan, Guo XiaoZhong. Advances in diagnosis and treatment of hepatorenal syndrome type of acute kidney injury in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 572-576. doi: 10.3969/j.issn.1001-5256.2017.03.039 |
[12] | Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046 |
[13] | Gao BaoXiu, He Yong, Li GuiXing, Nie Xin, Luo TongXing, Song HaoLan. Analysis of relationship of chronic severe hepatitis with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(7): 749-751. |
[14] | Chen ShengPeng, He WeiPing, Li YuFang, Wu JiJun. Clinical analysis of misdiagnosis and missed diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(4): 444-445. |
[15] | Wang JiYao. The difficulties in diagnosis and treatment of hepatorenal syndrome-raised by clinical cases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1019-1021. |
[16] | Xu XiaoYuan, Zheng YingYing. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. Journal of Clinical Hepatology, 2011, 27(8): 801-803+817. |
[17] | Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561. |
[18] | Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109. |